news
ADHD drugs unlikely to cause cardiac damage in children
The results of a long-term study on the use of ADHD medication has advised that they are unlikely to result in heart damage, or cardiac difficulties...
List view / Grid view
ADHD
news
FDA approves first generic Strattera for the treatment of ADHD
31 May 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration has approved the first generic versions of Strattera (atomoxetine) to treat (ADHD) in pediatric and adult patients...
news
Amarantus forms Elto Pharma for CNS disorders and MANF Therapeutics for ophthalmology
18 April 2017 | By Niamh Marriott, Junior Editor
Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).
news
ADHD market predicted to reach $13.9 billion by 2024
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%,…
news
Akili starts enrolment for trial of ADHD digital medicine treatment
6 May 2016 | By Victoria White, Digital Content Producer
Akili has started enrolment for its pivotal STARS-ADHD trial that will evaluate the safety and efficacy of the company’s proprietary platform, Project: EVO...
news
ADHD medication associated with decreased bone density in children
3 March 2016 | By Victoria White
Results from a large study indicate that children on ADHD medication had lower bone mineral density in the femur, femoral neck and lumbar spine...
news
ADHD drug Adzenys addresses unmet need for patients, says GlobalData
12 February 2016 | By Victoria White
The recent FDA approval of Adzenys will provide patients who have problems swallowing pills with easy-to-administer drug options, according to GlobalData analyst...
article
2015 Excellence in ADHD Patient Group Awards: Patient advocacy at Shire
20 October 2015 | By Victoria White
In the run up to ADHD Awareness Week, European Pharmaceutical Review spoke with Tom Croce, Head of Global Patient Advocacy at Shire, to find out more about the awards and what makes Shire a 'patient-centric' company...
